While the Pfizer/BioNTech vaccine breakthrough is rippling a new wave of hope in the battle against COVID-19, a number of private biotech companies are also ramping up vaccination development programs to battle the pandemic. While the vaccine-creation process is time-consuming, numerous startups are using their expertise and capabilities to find and develop technology-driven solutions targeting the virus at different stages and using different methodologies. Here’s a list of companies that have caught mainstream and investor attention in their fight against COVID-19.
San Francisco-based Meissa is starting preclinical studies and manufacturing of a vaccine against COVID-19. Like Codagenix, the virus will be live attenuated but will be delivered through the nose instead.
The company’s last round of funding was a Series A funding in September 2019 of $30MM.
Although not focused on vaccination treatment but rather a healthcare navigation tool powered by AI, the company offers COVID-19 assessment tools that ultimately directs patients to healthcare treatments and is said to have assessed 1 million Americans during the pandemic.
The company received a $37.5MM Series C funding on Tuesday, November 10 from Cigna Ventures, Humana, and Optum Ventures, rare funding from multiple health insurance companies.
Superspreading at gyms and restaurants
New studies take a look at where COVID-19 was most easily spread.
Mobility hub for flying taxis in Florida
German flying taxi startup Lilium announced plans to launch its first US hub with plans to connect Florida residents and tourists..to Disney World? [Read more]
Since last week, PrivCo has added: 563 Companies | 152 Funding Activities | 134 M&A Deals